The Haemato-oncology section provides genomic analysis of samples from patients with a range of haematological malignancies and lymphoproliferative conditions. The results obtained assist in diagnosis and classification, provide prognostic information for use in risk stratification, can direct therapeutic choice, and enable assessment of residual disease status post-treatment and/or post-transplant. We are a constituent laboratory of the West Midlands SIHMDS: MIRHO.
WMRGL provides testing commissioned by the NHS in England for the clinical indications listed in the Test Directory for haematological cancer and also accepts private referrals. Core commissioned testing is only available to patients from England who meet the defined eligibility criteria according to the Test Directory.
Specific information about accessing Whole Genome Sequencing in somatic cancer is available here.
Information on sample requirements and laboratory opening times can be found here, as can the MIRHO referral form for haematological cancer testing.
Test Information Sheets
AML MDS CML MPN CLL WGS Familial AML/MDS and ALL
Service User Communications
April 2023 Guidance for patients with germline predisposition to malignancy considered for SCT
November 2022 HO Test Turnaround Times [pdf] 744KB
May 2022 Haem Cancer WGS update letter and FAQs.pdf [pdf] 784KB
November 2021 Changes to T cell clonality assessment at Southampton Mol Path Laboratory
May 2021 NPM1 MRD monitoring within the National Genomic Medicine Service.pdf[pdf] 755KB
Oct 2020 Changes to the diagnostic MPN service [pdf] 176KB
Aug 2019 HO test turnaround times [pdf] 397KB
March 2018 CML reporting on IS [pdf] 219KB